The Department of Cancer Immunotherapeutics & Tumor Immunology (CITI) seeks to advance immunotherapeutic methods as a cure for cancer, eventually reducing or eliminating the need for chemotherapy, radiation therapy and surgery. The department will be housed in the new Arnold and Mabel Beckman Center, currently under construction. This new building will feature state-of-the-art laboratory research and educational facilities dedicated to immune system-based cancer therapies.
CITI is led by City of Hope's preeminent researchers and physicians, including Chair Andrew Raubitschek, M.D., and Director of Clinical Research Stephen Forman, M.D.
Immunotherapy, a powerful weapon against cancer because of its potential to exploit the body's natural defenses against infection, has been called the "fourth modality" of cancer treatment by the American Cancer Society. The department’s goal is to make it a highly effective primary treatment option.
Currently, T-cell therapy and radioimmunotherapy offer renewed hope to people who have exhausted other treatment options. They are also effective for eliminating microscopic residual disease which can lead to cancer recurrence, even after chemotherapy, radiation therapy and surgery have been successful.